Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)

Journal metrics

Journal metrics

Metrics and turnaround details

First decision 7 Days
Submission to acceptance 45 Days
Acceptance to publication 14 Days
Acceptance rate 8%

Scopus

Scopus profile

This journal is indexed in Scopus. Use these metrics for a quick publishing snapshot, then open the Scopus page for the authoritative profile.

Scopus
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Indexed in Scopus since 2022
CiteScore 1.0
Indexed since 2022

SCImago

SCImago Journal Rank preview

Use SCImago when you want a quick visual view of the journal ranking profile and external discoverability signals.

Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) SCImago Journal & Country Rank

DOAJ

Directory of Open Access Journals listing

The DOAJ record is useful for readers, librarians, and authors who want a direct open-access directory entry for the journal.

DOAJ
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Open directory record
Original full research article

A review of possible therapeutic agents for COVID-19 pandemic

Published
2021-07-06
Pages
117 - 138
Full text

Keywords

  • COVID-19
  • SARS
  • PubMed
  • treatment

Abstract

The epidemic of Coronavirus disease 2019 (COVID-19) caused by novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome, coronavirus 2) infection has been consid-ered by the World Health Organization (WHO) as a public health emergency of global inter-est. The efforts nowadays of different countries focus on the fast isolation and fast diagnosis of patients as well as to find possible therapeutic agent or vaccine. Several sites, articles, re-ports, reviews, and web pages discussing COVID-19 virus and possible treatments were in-vestigated, the data were collected between November-2020 and May-2021. Approximately 170 articles and reports were opened and read, but nearly 80 of them were used for this re-view. Several drugs showed hopeful potential results such as colchicine, dexamethasone, kaletra (Lopinavir/ritonavir), cefuroxime, favipiravir, and inhaled furosemide, but until now there is no WHO approved antiviral drug against COVID-19, although remdesivir is approved by Food and drug administration (FDA) as antiviral for COVID-19, but WHO doesn’t rec-ommend it’s use. The protocol followed by WHO until now is a symptomatic treatment, e.g., antipyretics, antitussive, adequate nutrition, and rehydration, antibiotics if suffering from secondary infection, antithrombotic prophylaxis for hospitalized COVID-19 patients, and corticosteroids in exacerbation cases. Fortunately, there are several vaccines that reached an advanced phase in research trials, and the world is hopeful for mass vaccination in early to mid-2021. Currently, there is no WHO-approved treatment for COVID-19, but there are many other promising drugs/agents under investigation. Supportive care and protocols were followed to manage the current crisis situation. However, many vaccines are approved for the prevention of COVID-19 available now such as Vaxzevria (Astrazeneca vaccine), tozinam-eran (Pfizer/BioNTech vaccine), Moderna: mRNA-1273 vaccine and Janssen COVID-19 vaccine while others are still in clinical trials.

Article history

Received
2021-02-06
Accepted
2021-07-06
بحث أصيل كامل

A review of possible therapeutic agents for COVID-19 pandemic

Published
2021-07-06
الصفحات
117 - 138
البحث كاملا

الكلمات الإفتتاحية

  • COVID-19
  • SARS
  • PubMed
  • treatment

الملخص

The epidemic of Coronavirus disease 2019 (COVID-19) caused by novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome, coronavirus 2) infection has been consid-ered by the World Health Organization (WHO) as a public health emergency of global inter-est. The efforts nowadays of different countries focus on the fast isolation and fast diagnosis of patients as well as to find possible therapeutic agent or vaccine. Several sites, articles, re-ports, reviews, and web pages discussing COVID-19 virus and possible treatments were in-vestigated, the data were collected between November-2020 and May-2021. Approximately 170 articles and reports were opened and read, but nearly 80 of them were used for this re-view. Several drugs showed hopeful potential results such as colchicine, dexamethasone, kaletra (Lopinavir/ritonavir), cefuroxime, favipiravir, and inhaled furosemide, but until now there is no WHO approved antiviral drug against COVID-19, although remdesivir is approved by Food and drug administration (FDA) as antiviral for COVID-19, but WHO doesn’t rec-ommend it’s use. The protocol followed by WHO until now is a symptomatic treatment, e.g., antipyretics, antitussive, adequate nutrition, and rehydration, antibiotics if suffering from secondary infection, antithrombotic prophylaxis for hospitalized COVID-19 patients, and corticosteroids in exacerbation cases. Fortunately, there are several vaccines that reached an advanced phase in research trials, and the world is hopeful for mass vaccination in early to mid-2021. Currently, there is no WHO-approved treatment for COVID-19, but there are many other promising drugs/agents under investigation. Supportive care and protocols were followed to manage the current crisis situation. However, many vaccines are approved for the prevention of COVID-19 available now such as Vaxzevria (Astrazeneca vaccine), tozinam-eran (Pfizer/BioNTech vaccine), Moderna: mRNA-1273 vaccine and Janssen COVID-19 vaccine while others are still in clinical trials.

Article history

تاريخ التسليم
2021-02-06
تاريخ القبول
2021-07-06